Literature DB >> 31441572

Swallowing-related outcomes associated with late lower cranial neuropathy in long-term oropharyngeal cancer survivors: cross-sectional survey analysis.

Puja Aggarwal1,2, Jhankruti S Zaveri1, Ryan P Goepfert1, Qiuling Shi3, Xianglin L Du2, Michael Swartz2, Stephen Y Lai1,4, C David Fuller4, Jan S Lewin1, Linda B Piller2, Katherine A Hutcheson1,4.   

Abstract

BACKGROUND: The purpose of this study was to quantify the association of late lower cranial neuropathy (late LCNP) with swallowing-related quality of life (QOL) and functional status among long-term oropharyngeal cancer (OPC) survivors.
METHODS: Eight hundred eighty-nine OPC survivors (median survival time: 7 years) who received primary treatment at a single institution between January 2000 and December 2013 completed a cross-sectional survey (56% response rate) that included the MD Anderson Dysphagia Inventory (MDADI) and self-report of functional status. Late LCNP events ≥3 months after cancer therapy were abstracted from medical records. Multivariate models regressed MDADI scores on late LCNP status adjusting for clinical covariates.
RESULTS: Overall, 4.0% (n = 36) of respondents developed late LCNP with median time to onset of 5.25 years post-treatment. LCNP cases reported significantly worse mean composite MDADI (LCNP: 68.0 vs no LCNP: 80.2; P < .001). Late LCNP independently associated with worse mean composite MDADI (β = -6.7, P = .02; 95% confidence interval [CI], -12.0 to -1.3) as well as all MDADI domains after multivariate adjustment. LCNP cases were more likely to have a feeding tube at time of survey (odds ratio [OR] = 20.5; 95% CI, 8.6-48.9), history of aspiration pneumonia (OR = 23.5; 95% CI, 9.6-57.6), and tracheostomy (OR = 26.9; 95% CI, 6.0-121.7).
CONCLUSIONS: In this large survey study, OPC survivors with late LCNP reported significantly poorer swallowing-related QOL and had significantly higher likelihood of poor functional status. Further efforts are necessary to optimize swallowing outcomes to improve QOL in this subgroup of survivors.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  dysphagia; lower cranial neuropathy; oropharyngeal cancer; radiotherapy; survivorship

Mesh:

Year:  2019        PMID: 31441572      PMCID: PMC7240804          DOI: 10.1002/hed.25923

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  37 in total

1.  Symptom burden as a driver of decisional regret in long-term oropharyngeal carcinoma survivors.

Authors:  Ryan P Goepfert; C David Fuller; G Brandon Gunn; Ehab Y Hanna; Jan S Lewin; Jhankruti S Zaveri; Rachel M Hubbard; Martha P Barrow; Katherine A Hutcheson
Journal:  Head Neck       Date:  2017-07-24       Impact factor: 3.147

2.  Symptom Burden Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Cancer Survivors.

Authors:  Puja Aggarwal; Jhankruti S Zaveri; Ryan P Goepfert; Qiuling Shi; Xianglin L Du; Michael Swartz; G Brandon Gunn; Stephen Y Lai; C David Fuller; Ehab Y Hanna; David I Rosenthal; Jan S Lewin; Linda B Piller; Katherine A Hutcheson
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-11-01       Impact factor: 6.223

3.  Long-Term, Prospective Performance of the MD Anderson Dysphagia Inventory in "Low-Intermediate Risk" Oropharyngeal Carcinoma After Intensity Modulated Radiation Therapy.

Authors:  Ryan P Goepfert; Jan S Lewin; Martha P Barrow; G Brandon Gunn; C David Fuller; Beth M Beadle; Adam S Garden; David I Rosenthal; Merrill S Kies; Vassiliki Papadimitrakopoulou; Stephen Y Lai; Neil D Gross; David L Schwartz; Katherine A Hutcheson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-06-15       Impact factor: 7.038

4.  Late radiation-associated dysphagia with lower cranial neuropathy in long-term oropharyngeal cancer survivors: video case reports.

Authors:  Katherine A Hutcheson; Margaret M Yuk; F Christopher Holsinger; G Brandon Gunn; Jan S Lewin
Journal:  Head Neck       Date:  2015-04       Impact factor: 3.147

5.  Predictive factors and radiological features of radiation-induced cranial nerve palsy in patients with nasopharyngeal carcinoma following radical radiotherapy.

Authors:  Yiu S Luk; John S F Shum; Henry C K Sze; Lucy L K Chan; W T Ng; Anne W M Lee
Journal:  Oral Oncol       Date:  2012-08-11       Impact factor: 5.337

6.  Cranial neuropathy following curative chemotherapy and radiotherapy for carcinoma of the nasopharynx.

Authors:  M Y Kang; J M Holland; K R Stevens
Journal:  J Laryngol Otol       Date:  2000-04       Impact factor: 1.469

Review 7.  Delayed lower cranial neuropathy after oropharyngeal intensity-modulated radiotherapy: A cohort analysis and literature review.

Authors:  Katherine A Hutcheson; Maggie Yuk; Rachel Hubbard; Gary B Gunn; C David Fuller; Stephen Y Lai; Heather Lin; Adam S Garden; David I Rosenthal; Ehab Y Hanna; Merrill S Kies; Jan S Lewin
Journal:  Head Neck       Date:  2017-04-28       Impact factor: 3.147

8.  Delayed lower cranial neuropathies following primary radiotherapy for oropharyngeal squamous cell carcinoma.

Authors:  Andrew T Huang; Shiyu Song; Laura M Dominguez; Josephine Nguyen; Richard A Goldman; Evan R Reiter
Journal:  Laryngoscope       Date:  2013-05       Impact factor: 3.325

9.  What is a clinically relevant difference in MDADI scores between groups of head and neck cancer patients?

Authors:  Katherine A Hutcheson; Martha P Barrow; Asher Lisec; Denise A Barringer; Kacie Gries; Jan S Lewin
Journal:  Laryngoscope       Date:  2015-11-06       Impact factor: 3.325

10.  Validation of the Sydney Swallow Questionnaire (SSQ) in a cohort of head and neck cancer patients.

Authors:  Raghav C Dwivedi; Suzanne St Rose; Justin W G Roe; Afroze S Khan; Christopher Pepper; Christopher M Nutting; Peter M Clarke; Cyrus J Kerawala; Peter H Rhys-Evans; Kevin J Harrington; Rehan Kazi
Journal:  Oral Oncol       Date:  2010-03-09       Impact factor: 5.337

View more
  5 in total

1.  Risk factors associated with patient-reported fatigue among long-term oropharyngeal carcinoma survivors.

Authors:  Puja Aggarwal; Katherine A Hutcheson; Ryan P Goepfert; Adam S Garden; Naveen Garg; Frank E Mott; Clifton D Fuller; Stephen Y Lai; Gary Brandon Gunn; Mark S Chambers; Ehab Y Hanna; Erich M Sturgis; Sanjay Shete
Journal:  Head Neck       Date:  2022-01-27       Impact factor: 3.147

2.  Home-based intensive treatment of chronic radiation-associated dysphagia in head and neck cancer survivors (HIT-CRAD trial).

Authors:  Hanne Massonet; Ann Goeleven; Leen Van den Steen; Alice Vergauwen; Margot Baudelet; Gilles Van Haesendonck; Olivier Vanderveken; Heleen Bollen; Lisette van der Molen; Fréderic Duprez; Peter Tomassen; Sandra Nuyts; Gwen Van Nuffelen
Journal:  Trials       Date:  2022-10-22       Impact factor: 2.728

3.  Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis.

Authors:  Kristina R Dahlstrom; Juhee Song; Peter F Thall; Clifton D Fuller; Katherine A Hutcheson; Faye M Johnson; G Brandon Gunn; Jack Phan; Steven J Frank; William H Morrison; Renata Ferrarotto; David I Rosenthal; Erich M Sturgis; Adam S Garden
Journal:  Cancer       Date:  2020-12-11       Impact factor: 6.860

4.  Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002).

Authors:  Sue S Yom; Pedro Torres-Saavedra; Jimmy J Caudell; John N Waldron; Maura L Gillison; Ping Xia; Minh T Truong; Christina Kong; Richard Jordan; Rathan M Subramaniam; Min Yao; Christine H Chung; Jessica L Geiger; Jason W Chan; Brian O'Sullivan; Dukagjin M Blakaj; Loren K Mell; Wade L Thorstad; Christopher U Jones; Robyn N Banerjee; Christopher Lominska; Quynh-Thu Le
Journal:  J Clin Oncol       Date:  2021-01-28       Impact factor: 44.544

5.  Manual Therapy for Fibrosis-Related Late Effect Dysphagia in head and neck cancer survivors: the pilot MANTLE trial.

Authors:  Katherine Hutcheson; Holly McMillan; Carla Warneke; Christine Porsche; Kiara Savage; Sheila Buoy; Jihong Wang; Karin Woodman; Stephen Lai; Clifton Fuller
Journal:  BMJ Open       Date:  2021-08-04       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.